Vera Therapeutics, Inc. Stock Price, News & Analysis

Vera Therapeutics (VERA) reported significant developments and financial results for Q2 2022. The company completed enrollment for the Phase 2b ORIGIN trial of atacicept in IgA nephropathy, with topline data expected in early Q1 2023. Positive interim results for MAU868 in kidney transplant patients were presented at the American Transplant Congress, with plans for further clinical trials. As of June 30, 2022, Vera held approximately $131.9 million in cash and equivalents and has access to a $45 million credit facility, expected to fund operations through Q2 2024.

Vera Therapeutics, a late-stage biotechnology company focused on immunological diseases, will present at the 13th Annual Wedbush PacGrow Healthcare Conference on August 10, 2022, from 12:00 – 12:30 PM ET. This virtual conference will also include one-on-one investor meetings. The company's lead product candidate, atacicept, targets autoimmune diseases like IgA nephropathy and lupus nephritis. A live audio webcast will be available, with a replay accessible for 90 days afterward. For more information, visit www.veratx.com.

Vera Therapeutics has completed patient enrollment for the Phase 2b ORIGIN clinical trial of atacicept, aimed at treating IgA nephropathy (IgAN), a serious kidney disease. The trial involves 115 patients who are at high risk of disease progression despite existing treatments. Topline results are expected in Q4 2022. Atacicept is designed to reduce proteinuria, a key marker of kidney damage. This milestone comes as IgAN has no approved treatments, affecting an estimated 400,000 patients in the U.S., EU, and Japan.

Vera Therapeutics (Nasdaq: VERA) announced positive interim results from a Phase 2 trial of MAU868, a first-in-class monoclonal antibody targeting BK Virus (BKV) in kidney transplant recipients. Presented at the American Transplant Congress 2022, data showed MAU868 was well tolerated and demonstrated significant antiviral activity, with 55% of patients achieving a prespecified reduction in BK plasma viral load. As there are currently no approved treatments for BKV, these results support the further development of MAU868 as a promising therapeutic option for affected patients.

Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company, has announced its participation at the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. The management team will present on June 8 at 4:00 PM ET and engage in one-on-one investor meetings. A live audio webcast will be available, with a replay accessible for 90 days via the investor calendar on the company’s website. Vera focuses on transformative treatments for serious immunological diseases, including its lead candidate, atacicept, for autoimmune disorders.

Vera Therapeutics (Nasdaq: VERA) announced promising new clinical data for atacicept, its lead product candidate, during the ERA-EDTA Congress. The investigational therapy demonstrated its ability to reduce both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies, which are linked to IgA nephropathy progression. In a Phase 2a trial, atacicept showed a significant decrease in anti-Gd-IgA1 levels, with reductions of up to 39% at 72 weeks. A post-hoc analysis from a Phase 2 study indicated potential renal function improvement in systemic lupus erythematosus patients. The company is advancing atacicept through further clinical trials.

Vera Therapeutics (VERA) remains on track with its Phase 2b ORIGIN clinical trial for atacicept, with topline data anticipated in Q4 2022. A Phase 3 trial for lupus nephritis is set to begin in the second half of 2022, following positive FDA interactions. The company boasts a robust balance sheet with approximately $151 million in cash and a $45 million credit facility, expected to fund operations through Q2 2024. Despite a net loss of $17.1 million for Q1 2022, the company continues to advance its clinical pipeline and maintain strong enrollment in its studies.

Vera Therapeutics (Nasdaq: VERA) announced participation in two key conferences in May 2022. The first is the LifeSci Partners Immunology & Inflammation Symposium on May 10, from 2:30-2:55 PM ET, featuring a fireside chat format. The second is the H.C. Wainwright Global Investment Conference from May 23-26, with a presentation scheduled for May 25, 1:30-2:00 PM ET. Both events will have live audio webcasts available online. Vera focuses on transformative treatments for serious immunological diseases, including its lead candidate, atacicept.

Vera Therapeutics (Nasdaq: VERA) announced two significant oral presentations of clinical data for its lead candidate, atacicept, at the upcoming ERA-EDTA Congress from May 19-22, 2022, in Paris. The presentations will include results from the Phase 2a JANUS trial on IgA nephropathy and a post-hoc analysis of the APRIL-SLE study in systemic lupus erythematosus. Atacicept, a weekly subcutaneous injection, targets B-cell activity linked to autoimmune diseases and has shown promising results in clinical studies.